Compare CCEL & EUDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCEL | EUDA |
|---|---|---|
| Founded | 1989 | 2021 |
| Country | United States | Singapore |
| Employees | N/A | 117 |
| Industry | Managed Health Care | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 24.3M |
| IPO Year | 2022 | N/A |
| Metric | CCEL | EUDA |
|---|---|---|
| Price | $3.44 | $17.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 7.5K | ★ 313.1K |
| Earning Date | 04-14-2026 | 12-19-2023 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $25,384,279.00 | N/A |
| Revenue This Year | N/A | $134.73 |
| Revenue Next Year | N/A | $195.03 |
| P/E Ratio | $344.00 | ★ $123.62 |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $2.72 | $0.33 |
| 52 Week High | $5.52 | $25.70 |
| Indicator | CCEL | EUDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 70.28 |
| Support Level | $3.18 | $1.45 |
| Resistance Level | $3.57 | $25.70 |
| Average True Range (ATR) | 0.19 | 2.00 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 6.12 | 36.42 |
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.